Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: A Meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 11, 2011, Pages 2901-2907

  Ge, Wei ^a   Cao, De Dong ^a   Wang, Hui Min ^a   Jie, Fang Fang ^a   Zheng, Yong Fa ^a   Chen, Yu ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Efficacy; Non small cell lung cancer; rh endostatin; Safety; Systematic review

Indexed keywords

EID: 84863319724     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Azim HA, Elattar I, Loberiza F, et al (2009). Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview. Lung Cancer, 64, 194-8.
2. Cai L, Sun LC, Yang CY, et al (2007). Observation on the efficacy of Endostar combined with chemotherapy in the treatment of non-small cell lung cancer. Chinese J Pract Int Med, 27, 1541-2.
3. Chen SJ, Huang HX, Li GS, et al (2008). Clinical study on endostar combined with vinorelbine and oxaliplatin in the treatment of advanced non-small cell lung cancer. J Hebei Medical University, 29, 819-21.
4. Fan QL, Kao J, Zhou WL. (2008). Observation of the near efficacy on injection of recombinant human vascular endothelial suppression combined NP in the treatment of advancednon-small cell lung cancer. Modern J Integrated Traditional Chinese Western Med, 17, 1170-1.
5. Folkman J. (2006). Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 312, 594-607.
6. Han B, Xiu Q, Wang H, Shen J, et al (2011). A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol, 6, 1104-9.
7. Han LC, Xing DJ. (2009). Clinical observation of endostar combined with TP chemotherapy in the treatment of advanced stage NSCLC. Chinese J Clin Oncol, 36, 1205-7.
8. Huang C. (2005). A study on relation of the level of CECs and efficacy of NP regimen with Endostatin in advanced NSCLC. Graduate Article, 1, 1-60.
9. Huang G, Chen L. (2010). Recombinant human endostatin improves anti-tumor effi cacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol, 136, 1201-11.
10. Huang GS. (2007). The efficacy of NP plus ENDOSTAR and chemotherapy in the treatment of non-small cell lung cancer. Henan J Surg, 13, 1-2.
11. Liao H, Feng W, Li Y, et al (2009). Study of the Feasibility of Endostar plus Gemcitabine and Cisplatin Regimen for Advanced Non-small-cell Lung Cancer. Chin J Lung Cancer, 12, 574-6.
12. Jiang F, Sun Y, Wang G, et al (2011). Recombinant human endostatin combined with DP scheme in the treatment of 67 advanced NSCLC patients. Cancer Res Clinic, 23, 264-6.
13. Jin J. (2009). Observation the efficacy of chemotherapy combined with Endostar in patients with non-small cell lung cancer. China Foreign Medical J, 7, 13.
14. Li W, Yin YM, Guo RH, et al (2008). Endostar combined with TP or GP regimen in 31 cases of advanced non-small cell lung cancer pafients. Chinese Clin Oncol, 13, 797-9.
15. Liu J, Jin CL, Niu HR, et al (2009). Observation of Endostar combined with weekly dose of Docetaxd regimen for non-small cell lung cancer. Medical Information Medicine Surgery, 22, 506-8.
16. Liu J, Huang JZ, Quan JZ. (2009). Clinical study of concurrent chemoradiotherapy combined with YH-16 in the treatment of local advanced non-small cell lung cancer. China Medical Herald, 6, 253-4.
17. Liu H, Ao R, Zhang L, et al (2009). Combination of recombinant human endostatin and GP in the treatment of advanced non-small cell lung cancer. Chin J Prim Med Pharm, 16, 1574-5.
18. Lou Y, Wang T, Mao Y, et al (2010). Endostar combined with paclitaxel and carboplatin in targeted treatment of advanced non-small cell lung cancer. An observation of clinical effect. China Modern Doctor, 48, 39-40.
19. Ma JB, Yang JL, Li ZL, et al (2009). A randomized clinical trial of endostar combined with concurrent chemoradiotherapy in treatment of local advanced non-small cell lung cancer. J Clin Med Pract, 13, 20-4.
20. Mu HY, Shen CY, Feng YL. (2009). Clinical observation on the target therapy of Rh-Endostin vombined with chemotherapy in advanced non-small cell lung cancer. Chin J Lung Cancer, 12, 780-4.
21. O'Reilly MS, Boehm T, Shing Y, et al (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-85.
22. Pignon J, Tribodet H, Scagliotti G. (2008). Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 26, 3552-9.
23. Tang Z, Yu ZH, Yang ZX. (2009). Observation of rh-endostatin combined with TC regimen for non-small cell lung cancer. Chinese Clin Oncol, 14, 341-3.
24. Te Velde EA, Vogten JM, Gebbink MF. (2002). Enhanced antitumor effi cacy by combining conventional chemotherapy with angiostatin or Endostatin in a liver metastasis model. Br J Surg, 89, 1302-9.
25. Wang KZ, Li CY, Li Y, et al (2008). Clinical study of endu injection with NP chemotherapy in the treatment of advanced NSCLC. Ji Lin Medical J, 29, 1059-60.
26. Wang WJ, Sun Y, Liu YY, et al (2005). Rults of randomized multicenter double-blind phase trial of rh-endtatin(YH-16)in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer, 8, 283-90.
27. Wen F, Wang W, Shang L, et al (2011). Observation of short term effects of endostar combined with NP regimen for non-small cell lung cancer. J Clinical Med Prac, 15, 79-80.
28. Xiao M, Xue YY, Liu SQ. (2009). Combination of Endostar and GP in the treatment of advanced non-small cell lung cancer. J Jiangsu University, 19, 348-9.
29. Xie YR, Huang JJ. (2009). Clinical study on endostar combined with GP in the treatment of advanced non-small cell lung cancer. Chinese J Gerontol, 29, 2035-7.
30. Yang L, Wang WJ, Cui CX, et al (2005). Rh-endostatin(YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer: a multicenter phase II trial. Chinese J New Drugs, 14, 204-7.
31. Zhang T, Liu DH, Wang B, et al (2009). Latest efficacy and safety of YH-16 combined with GP for advanced non-small cell lung cancer. Chinese General Practice, 12, 969-70.
32. Zhao X, Mei K, Cai X, et al (2011). A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Invest New Drugs, (in press).
33. Zhu XS, Hu XW, Cao LJ, et al (2009). Clinical observation on the efficacy of Endostatin combined with chemotherapy in the treatment of non-small lung cancer. J Clin Pulmonary Med 14, 194-5.